| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
177,680,000 |
| Market
Cap: |
8.95(B) |
| Last
Volume: |
2,452,559 |
Avg
Vol: |
1,930,580 |
| 52
Week Range: |
$51.95 - $99.04 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 568 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Exact Sciences is a cancer screening and diagnostics company. Co.'s primary screening product, the Cologuard® test, is a non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Co.'s portfolio of Oncotype tests include: Oncotype DX gene expression tests for breast, prostate and colon cancers; Oncotype DX AR-V7 Nucleus Detect® test, a liquid-based test for advanced stage prostate cancer; and Oncotype MAP™ Pan-Cancer Tissue test (oncomap test), a test delivering tumor profiling to aid therapy selection for patients with metastatic, refractory or recurrent cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
83,112 |
108,398 |
168,494 |
290,334 |
| Total Sell Value |
$4,965,701 |
$6,570,910 |
$11,439,131 |
$18,676,003 |
| Total People Sold |
10 |
10 |
11 |
11 |
| Total Sell Transactions |
43 |
52 |
62 |
100 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Elliott Jeffrey Thomas |
Chief Financial Officer |
• – – |
2018-10-31 |
4 |
A |
$13.26 |
$10,011 |
D/D |
755 |
33,211 |
|
- |
|
| Napier Katherine S |
Director |
– • – |
2018-10-31 |
4 |
GD |
$0.00 |
$0 |
D/D |
4,095 |
102,102 |
|
- |
|
| Lidgard Graham Peter |
Chief Science Officer |
• – – |
2018-10-31 |
4 |
AS |
$75.35 |
$1,669,499 |
D/D |
(22,156) |
124,528 |
|
- |
|
| Lidgard Graham Peter |
Chief Science Officer |
• – – |
2018-10-08 |
4 |
AS |
$68.20 |
$4,022,933 |
D/D |
(58,000) |
146,684 |
|
- |
|
| Coward D Scott |
Chief Administrative Officer |
• – – |
2018-10-01 |
4 |
AS |
$79.51 |
$174,118 |
D/D |
(2,190) |
75,857 |
|
- |
|
| Coward D Scott |
Chief Administrative Officer |
• – – |
2018-09-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,688 |
78,047 |
|
- |
|
| Wyzga Michael S |
Director |
– • – |
2018-08-28 |
4 |
AS |
$74.85 |
$184,730 |
D/D |
(2,468) |
9,112 |
|
- |
|
| Fallon John A. |
Director |
– • – |
2018-07-30 |
4 |
AS |
$58.86 |
$139,675 |
D/D |
(2,373) |
33,767 |
|
- |
|
| Carey Thomas D. |
Director |
– • – |
2018-07-30 |
4 |
AS |
$58.86 |
$201,713 |
D/D |
(3,427) |
48,983 |
|
- |
|
| Napier Katherine S |
Director |
– • – |
2018-07-30 |
4 |
AS |
$58.86 |
$167,574 |
D/D |
(2,847) |
106,197 |
|
- |
|
| Doyle James Edward |
Director |
– • – |
2018-07-30 |
4 |
AS |
$58.86 |
$77,577 |
D/D |
(1,318) |
37,093 |
|
- |
|
| Elliott Jeffrey Thomas |
Chief Financial Officer |
• – – |
2018-07-30 |
4 |
AS |
$57.78 |
$519,096 |
D/D |
(8,984) |
32,456 |
|
- |
|
| Elliott Jeffrey Thomas |
Chief Financial Officer |
• – – |
2018-07-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
18,750 |
41,440 |
|
- |
|
| Wyzga Michael S |
Director |
– • – |
2018-07-26 |
4 |
A |
$0.00 |
$0 |
D/D |
606 |
11,580 |
|
- |
|
| Casdin Eli |
Director |
– • – |
2018-07-26 |
4 |
A |
$0.00 |
$0 |
D/D |
6,262 |
6,262 |
|
- |
|
| Thompson David |
Director |
– • – |
2018-07-26 |
4 |
A |
$0.00 |
$0 |
D/D |
4,651 |
201,095 |
|
- |
|
| Levangie Daniel J |
Director |
– • – |
2018-07-26 |
4 |
A |
$0.00 |
$0 |
D/D |
4,401 |
77,998 |
|
- |
|
| Doyle James Edward |
Director |
– • – |
2018-07-26 |
4 |
A |
$0.00 |
$0 |
D/D |
3,230 |
38,411 |
|
- |
|
| Napier Katherine S |
Director |
– • – |
2018-07-26 |
4 |
A |
$0.00 |
$0 |
D/D |
3,230 |
109,044 |
|
- |
|
| Fallon John A. |
Director |
– • – |
2018-07-26 |
4 |
A |
$0.00 |
$0 |
D/D |
3,230 |
36,140 |
|
- |
|
| Coward D Scott |
SVP and General Counsel |
• – – |
2018-07-02 |
4 |
AS |
$59.10 |
$126,176 |
D/D |
(2,135) |
73,359 |
|
- |
|
| Coward D Scott |
SVP and General Counsel |
• – – |
2018-06-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,687 |
75,494 |
|
- |
|
| Wyzga Michael S |
Director |
– • – |
2018-05-10 |
4 |
AS |
$51.53 |
$381,447 |
D/D |
(7,402) |
10,974 |
|
- |
|
| Johnson Scott C. |
SVP - Research and Development |
• – – |
2018-04-30 |
4 |
A |
$13.26 |
$3,739 |
D/D |
282 |
7,934 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2018-04-30 |
4 |
A |
$5.95 |
$21,253 |
D/D |
3,572 |
886,011 |
|
- |
|
777 Records found
|
|
Page 20 of 32 |
|
|
1.57 (3.02%) 
